X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (48) 48
science & technology (48) 48
humans (34) 34
hypercholesterolemia (32) 32
female (30) 30
male (30) 30
cardiovascular (29) 29
middle aged (22) 22
cardiac & cardiovascular systems (21) 21
cardiovascular system & cardiology (21) 21
cholesterol, ldl - blood (20) 20
treatment outcome (20) 20
internal medicine (19) 19
low density lipoproteins (19) 19
pharmacology & pharmacy (18) 18
double-blind method (17) 17
hyperlipoproteinemia type ii - drug therapy (17) 17
statins (16) 16
aged (14) 14
care and treatment (14) 14
cholesterol (14) 14
abridged index medicus (13) 13
adult (13) 13
anticholesteremic agents - therapeutic use (13) 13
familial hypercholesterolemia (13) 13
lipids (13) 13
low density lipoprotein (13) 13
pcsk9 (13) 13
adolescent (12) 12
genetic aspects (12) 12
cardiology and cardiovascular medicine (11) 11
cardiovascular disease (11) 11
clinical trials (11) 11
hypercholesterolemia - drug therapy (11) 11
hyperlipoproteinemia type ii - blood (11) 11
alirocumab (10) 10
risk factors (10) 10
antibodies, monoclonal - adverse effects (9) 9
antibodies, monoclonal - therapeutic use (9) 9
atherosclerosis (9) 9
child (9) 9
drug therapy (9) 9
anticholesteremic agents - adverse effects (8) 8
ldl-c (8) 8
lipoproteins (8) 8
patients (8) 8
children (7) 7
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (7) 7
hypercholesterolemia - blood (7) 7
monoclonal antibodies (7) 7
peripheral vascular disease (7) 7
safety (7) 7
time factors (7) 7
young adult (7) 7
analysis (6) 6
diabetes (6) 6
dosage and administration (6) 6
dose-response relationship, drug (6) 6
drug therapy, combination (6) 6
endocrinology & metabolism (6) 6
follow-up studies (6) 6
heterozygote (6) 6
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (6) 6
life sciences (6) 6
antibodies, monoclonal - administration & dosage (5) 5
apolipoproteins (5) 5
cardiovascular diseases (5) 5
evolocumab (5) 5
hyperlipoproteinemia type ii - genetics (5) 5
santé publique et épidémiologie (5) 5
anticholesteremic agents - administration & dosage (4) 4
blood cholesterol (4) 4
cholesterol, ldl (4) 4
cholesterol, ldl - drug effects (4) 4
ezetimibe - adverse effects (4) 4
ezetimibe - therapeutic use (4) 4
general & internal medicine (4) 4
health aspects (4) 4
human health and pathology (4) 4
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (4) 4
hyperlipoproteinemia type ii - complications (4) 4
lipoprotein - blood (4) 4
medical colleges (4) 4
medicine, general & internal (4) 4
open-label extension (4) 4
proprotein convertase 9 (4) 4
proprotein convertase 9 - antagonists & inhibitors (4) 4
proprotein convertases - antagonists & inhibitors (4) 4
type 2 diabetes (4) 4
usage (4) 4
aged, 80 and over (3) 3
antibodies (3) 3
anticholesteremic agents (3) 3
azetidines - therapeutic use (3) 3
biomarkers - blood (3) 3
cardiac patients (3) 3
cardiology (3) 3
cardiovascular diseases - blood (3) 3
comparative analysis (3) 3
drug administration schedule (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9965, pp. 331 - 340
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2014, Volume 63, Issue 13, pp. 1278 - 1288
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2015, Volume 372, Issue 16, pp. 1489 - 1499
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9983, pp. 2153 - 2161
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2010, Volume 55, Issue 11, pp. 1121 - 1126
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 67, Issue 13, pp. 1978 - 1978
Methods A total of 272 subjects aged 615 years with HeFH and low-density lipoprotein cholesterol (LDL-C) >=4.0 mmol/L (155 mg/dL) were enrolled in a 3-year... 
Cardiovascular | Internal Medicine | Low density lipoprotein | Teenagers | Statins
Journal Article
Expert Review of Cardiovascular Therapy, ISSN 1477-9072, 05/2015, Volume 13, Issue 5, pp. 477 - 488
Evolocumab is a fully human monoclonal IgG2 antibody that inhibits proprotein convertase subtilisin/kexin type 9, a protein that targets LDL receptors for... 
cardiovascular disease | PCSK9 | LDL cholesterol | hypercholesterolemia | evolocumab
Journal Article
Expert review of cardiovascular therapy, ISSN 1477-9072, 08/2013, Volume 11, Issue 8, pp. 1061 - 1066
Familial hypercholesterolemia is an autosomal dominant disorder. Heterozygous familial hypercholesterolemia (FH) has an estimated incidence of 1 per 300-500... 
screening | metabolic disease | children | genetic testing | familial hypercholesterolemia | Usage | Hypercholesterolemia | Genetic aspects | Diagnosis | Children | Medical screening | Methods | Genetic screening | Diseases
Journal Article
European heart journal, ISSN 0195-668X, 2015, Volume 36, Issue 43, pp. 2996 - 3003
Journal Article
Journal Article
The American journal of cardiology, ISSN 0002-9149, 04/2018, Volume 121, Issue 8, pp. 940 - 948
Patients with previous atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) are at high risk of future... 
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Simvastatin - therapeutic use | Rosuvastatin Calcium - therapeutic use | Humans | Middle Aged | Stroke - complications | Antibodies, Monoclonal - therapeutic use | Male | Risk | Peripheral Arterial Disease - complications | Hypercholesterolemia - drug therapy | Clinical Trials, Phase III as Topic | Coronary Disease - complications | Peripheral Arterial Disease - blood | Adult | Cholesterol, LDL - blood | Female | Hyperlipoproteinemia Type II - drug therapy | Drug Therapy, Combination | Hyperlipoproteinemia Type II - complications | Coronary Disease - blood | Hypercholesterolemia - blood | Atherosclerosis - drug therapy | Hyperlipoproteinemia Type II - blood | Atorvastatin - therapeutic use | Peripheral Arterial Disease - drug therapy | Atherosclerosis - complications | Treatment Outcome | Stroke - drug therapy | Atherosclerosis - blood | Stroke - blood | Maximum Tolerated Dose | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Heterozygote | Hypercholesterolemia - complications | Aged | Lipoproteins (low density) | Effectiveness | Demography | Risk groups | Simvastatin | Health risks | Clinical trials | Lipids | Cardiovascular disease | Disease control | Patients | Low density lipoprotein | Cholesterol | Subgroups | Demographics | Hypercholesterolemia | Arteriosclerosis | Atherosclerosis | Atorvastatin | Safety | Cardiovascular diseases | Statins | Index Medicus | Abridged Index Medicus
Journal Article